RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All Swissmedic updates
Swissmedic
REGULATORY UPDATE
I-SMI.TI.22e Notifications according to Article 41, MPLO
Published: 9/23/2026Detected: 9/4/2026

Summary preview

Defines or clarifies Swiss regulatory expectations for notifications submitted under Article 41 of the MPLO framework.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
manufacturing
quality
clinical
safety
labeling
#Swissmedic
#MPLO
#Article 41
#notifications
#regulatory submissions

Official Source Document
Source Verified

Access the original document directly from SWISSMEDIC.

View Official Document

More from Swissmedic

  • Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”10/1/2026
  • Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances10/1/2026
  • Revision of the Guidance document Authorisation Biosimilar10/1/2026
  • Swissmedic Portal Release – New Features Available from 23 September 20269/24/2026
  • ElViS 2.09/4/2026

Get Swissmedic alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.